Sangamo Therapeutics

CA - RichmondBiotechnology1 H-1B visas (FY2023)

Focus: Sangamo Therapeutics is a biotechnology company specializing in gene therapy and cell therapy using zinc finger nuclease (ZFN) technology across neurology, rare diseases, infectious diseases, metabolic diseases, and nephrology. The company operates as a mid-cap biotech with a diversified pipeline spanning multiple therapeutic modalities.

Neurology Infectious Diseases Rare Diseases Metabolic Diseases

Profile data last refreshed 12h ago · AI intelligence enriched 1w ago

Open Jobs

Recent layoff filing — 4 affected

6/22/2026 — 7000 Marina Blvd Brisbane CA 94005, CA · 4 affected · Layoff Amendment

Source: state DOL filings via Big Local News

Should You Work at Sangamo Therapeutics?

AI assessment

Best suited for scientists and clinical developers seeking deep platform expertise and early-stage program involvement, but carry heightened restructuring risk given minimal current hiring and recent layoff notices despite strong pipeline.

Why Work Here

Deep expertise in advanced gene-editing technologies (AAV, ZFN-based therapies) with 20+ active programs across five therapeutic areas—rare exposure for career-building in next-generation modalities

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

30 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Blood sample

Kidney Transplant Rejection

N/A

Clinical Trials (1)

NCT05987527Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)

N/A

Help build intelligence for Sangamo Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Significant Phase 2 presence (12 programs) across high-unmet-need indications including Alzheimer's, Parkinson's, HIV, and hemophilia—opportunity to drive mid-stage clinical development with multiple near-term readouts

Established IP moat in ZFN platform with programs spanning neurology (CERE-110, CERE-120), blood disorders (ST-400, SB-FIX), and infectious disease (SB-728-T)—meaningful platform leverage for long-term career trajectory

Watch Out For

Minimal hiring activity (1 active role) and recent WARN filing (June 2026, 4 employees) signals organizational contraction or restructuring despite pipeline depth—limited near-term mobility and potential headcount volatility
No Phase 3 programs and no marketed products create execution risk; all value is pre-commercialization with no validated revenue stream to underpin stability or bonus/equity upside realization

Generated by Claude from Sangamo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

There are no disallowed treatments

HIV-1-infection

N/A

Clinical Trials (1)

NCT04201782Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

N/A

ST-920

Fabry Disease

N/A

Clinical Trials (1)

NCT05039866Long-Term Follow-up of Subjects Who Were Treated With ST-920

N/A

SB-318

Hemophilia B

N/A

Clinical Trials (1)

NCT04628871Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

N/A

BIVV003

Blood and Lymphatic Diseases

N/A

Clinical Trials (1)

NCT05145062Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

N/A

CERE-120: AAV2-NTN

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT00252850Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease

Phase 1

SB-728mR-HSPC Infusion 3 days following busulfan conditioning

HIV

Phase 1

CERE-110: Adeno-Associated Virus Delivery of NGF

Alzheimer's Disease

Phase 1

Clinical Trials (1)

NCT00087789CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Phase 1

ZFN modified T cells

HIV

Phase 1

Clinical Trials (1)

NCT00842634Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

Phase 1

SB-728-T

HIV Infection

Phase 1

Clinical Trials (1)

NCT01044654Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Phase 1

hVEGF-A

Diabetic Neuropathy

Phase 1

Clinical Trials (1)

NCT00110500Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy

Phase 1

SB-FIX

Hemophilia B

Phase 1

Clinical Trials (1)

NCT02695160Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

Phase 1

SB-728-T

HIV

Phase 1/2

Clinical Trials (1)

NCT01252641Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

Phase 1/2

SB-318

MPS I

Phase 1/2

Clinical Trials (1)

NCT02702115Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I

Phase 1/2

SB-913

Mucopolysaccharidosis II

Phase 1/2

Clinical Trials (1)

NCT03041324Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

Phase 1/2

SB-728-T

HIV

Phase 1/2

Clinical Trials (1)

NCT01543152Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

Phase 1/2

Plerixafor

Sickle Cell Disease

Phase 1/2

Clinical Trials (1)

NCT03653247A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Phase 1/2

SB-728mR-T

Human Immunodeficiency Virus (HIV)

Phase 1/2

Clinical Trials (1)

NCT02225665Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Phase 1/2

ST-920

Fabry Disease

Phase 1/2

Clinical Trials (1)

NCT04046224Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

Phase 1/2

ST-400 Investigational product

Transfusion Dependent Beta-thalassemia

Phase 1/2

Clinical Trials (1)

NCT03432364A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

Phase 1/2

ST-503

Chronic Neuropathic Pain

Phase 1/2

Clinical Trials (1)

NCT06980948Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

Phase 1/2

TX200-TR101

Kidney Transplant Rejection

Phase 1/2

Clinical Trials (1)

NCT04817774Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients

Phase 1/2

CERE-120: Adeno-Associated Virus Delivery of Neurturin

Idiopathic Parkinson's Disease

Phase 1/2

Clinical Trials (1)

NCT00985517Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

Phase 1/2

SB-509

Diabetes Mellitus, Type 1

Phase 2

Clinical Trials (1)

NCT00665145Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

Phase 2

SB-509

Amyotrophic Lateral Sclerosis

Phase 2

Clinical Trials (1)

NCT00748501Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

SB-509

Diabetes Mellitus, Type 1

Phase 2

Clinical Trials (1)

NCT00406458Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Phase 2

SB-509

Diabetes Mellitus, Type 1

Phase 2

Clinical Trials (1)

NCT01079325Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Phase 2

SB-509

Diabetes Mellitus, Type 1

Phase 2

Clinical Trials (1)

NCT00476931Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Phase 2

CERE-110: Adeno-Associated Virus injection Surgery

Alzheimer's Disease

Phase 2

Clinical Trials (1)

NCT00876863Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Phase 2

CERE-120

Idiopathic Parkinson's Disease

Phase 2

Clinical Trials (1)

NCT00400634Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease

Phase 2

Interview Prep Quick Facts

Portfolio: 29 clinical trials

Top TAs: Neurology, Infectious Diseases, Rare Diseases

H-1B (2023): 1 approval

Open Roles: 1 active job

Therapeutic Area Focus

12 pipeline

6 pipeline

5 pipeline

4 pipeline

2 pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2026-06-22

4 employees affected— Brisbane, CA

Source: state DOL filings, aggregated via Big Local News

June 2026 WARN filing for 4 employees at Brisbane, CA facility indicates recent or pending layoff.

Recent layoff notice amid robust pipeline suggests organizational restructuring or cash optimization—stability risk warrants due diligence on cash runway and funding status.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Sangamo Therapeutics

Should You Work at Sangamo Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (1)

Data Entry Clerk

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)